ER-positive
Discrepancies in central review re testing of patients with ER positive and HER2 negative breast cancer in the OPTIMA prelim randomised clinical trial
... as ER-positive and HER2-negative is limited; reports have largely described data from central re-testing of breast cancers, which have been recorded as HER2-positive in local laboratories such as in ...
5
Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer
... in ER-positive breast cancer, we analyzed the relationship between p53 expression and ...cohort, positive p53 staining cases exhibited a higher likelihood for disease events (HR = ...
7
NHERF1, a novel GPER associated protein, increases stability and activation of GPER in ER-positive breast cancer
... of ER-positive breast cancer cell lines (MCF-7, T47D, ZR-75-1 and BT474 ...a positive correlation between expression of GPER and NHERF1 in ER-positive breast cancer cells (Figure ...
15
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
... with ER-positive breast ...of ER-positive breast cancers, and the RET ligand, glial-derived neurotrophic factor (GDNF) is upregulated by inflammatory ...in ER- positive cancers ...
20
Cancer immune interactions in ER positive breast cancers: PI3K pathway alterations and tumor infiltrating lymphocytes
... were ER-positive (ERα positivity defined as ≥ 10% positive tumor cells as determined using immuno- histochemistry) [22, 23] (Additional file 1: Figure ...nuclear positive tumor cells ...
12
Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
... test positive for lymphovascular invasion, Adjuvant! Online would overestimate ...with ER-positive breast cancer [3] and that it overestimated the added value of chemotherapy for older patients ...
7
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER positive HER2 negative breast cancer
... the ER but which do not contain a HER2 gene ...with ER- positive/HER2-negative tumors only a small fraction will achieve pCR, while the prognosis is better than that of triple-negative breast cancer ...
12
Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3
... of ER-positive breast cancer cells. However the relationship of ER positive and miR-203 upregulation remains to be ...that ER transcriptionally enhances miR-203 in ...
11
An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
... [27]. ER status is one of the strong factors in predicting patients’ response to endocrine therapy and its determin- ation has become a standard practice in the management of breast cancer ...of ER was ...
6
Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics
... in ER-positive subtype ...lncRNAs. ER expression- related lncRNAs were listed in our study, and these ER-asso- ciated genes may play important roles in the development of ...of ...
11
Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis.
... and ER-targeted therapies such as antiestrogens and aromatase inhibitors have therefore been widely used in breast cancer ...on ER-positive breast cancer cells and non-tumorigenic mammary epithelial ...
14
High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer
... In the current study although NIK and RelB are not associated with patient recurrence or survival, in contrast levels of IKKα expression were associated with disease-free survival in the full cohort and when the cohort ...
42
Original Article Renalase overexpression in ER-positive breast cancer
... A positive correlation between renalase and tumors was found in pancreatic cancer [16], and the study found that renalase mRNA was highly expressed in pancreatic cancer ...renalase. ER-positive ...
11
<p>Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer</p>
... treat ER-positive breast cancers in the Chinese patient cohort, although the ER-positive rate in Chinese breast cancer patients is lower than in Western patient (50 – 60% vs ...of ER α ...
7
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
... Results: Here, we applied a powerful integrative network algorithm to matched DNA methylation and RNA-Seq data for 724 estrogen receptor (ER)-positive (ER+) breast cancers and 111 normal adjacent ...
16
Estrogen receptor (ER) was regulated by RNPC1 stabilizing mRNA in ER positive breast cancer
... with ER negative have shorter survival ...with ER- positive, are suitable candidates for hormonal therapies, which aim to block estrogen stimulation of breast cancer ...selective ER modulators ...
15
Original Article TSPAN13 is overexpressed in ER-positive breast cancers and contributes to tumor progression
... To study why TSPAN13 was upregulated in ER positive breast cancers, we use the ZR-75-30 ER-positive cell line for endogenous TSPA- N13 study. TSPAN13 knockdown led to G0/ G1-phase arrest and ...
9
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
... with ER+, human epidermal receptor-2-negative (HER2-) early advanced breast cancer, assessed on the basis of clinical algorithms to be at intermediate risk of DR and who would benefit from additional prognostic ...
20
Autocrine IGF I/insulin receptor axis compensates for inhibition of AKT in ER positive breast cancer cells with resistance to estrogen deprivation
... of ER a (Figure 5C), suggesting that its compensatory upregulation may be dependent on ...decreased ER a levels in MCF-7 cells ...transactivate ER a ...lates ER transcriptional activity ...
14
ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy
... against ER (1:100 dilution), PR (1:150 dilution), HER2 (1:150 dilution) and Ki-67 (1:100 dilution) were purchased from Changdao Antibody Diagnostic Reagents ...for ER positivity and PR positivity was 1% ...
9